NB003
GISTAR-1
Ningbo Newbay Technology Development · Phase 2/3 · Recruiting · Enrollment 255
| Arm | Reported safety |
|---|---|
| NB003 15 mg BID (Part 1) | n/r |
| Regorafenib 160 mg | n/r |
A count stays a count. This page does not turn a count into a percent.
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
NB003
Ningbo Newbay Technology Development · Phase 2/3 · Recruiting · Enrollment 255
| Arm | Reported safety |
|---|---|
| NB003 15 mg BID (Part 1) | n/r |
| Regorafenib 160 mg | n/r |
A count stays a count. This page does not turn a count into a percent.